whether it is a New Chemical Entity (NCE), classic drug substance or a live biotherapeutic, to give it the best possible chances of clinical and commercial success.
To do this, we have an extensive portfolio of pharmaceutical technologies that allow us to develop formulations that present particular challenges.
Complementing our more traditional drug products, these allow us to develop novel medications that will be effective in key therapeutic areas, as well as introducing significant performance advantages over existing products.
Quay Pharma’s Broad Technologies Include:
Conventional dosage forms.
Drug solubilisation and bioavailability enhancement.
Controlled release and gastrointestinal targeting.
Our Modified Release Technologies
Modified Release Tablets
Coated and uncoated modified release tablets in a wide range of shapes, sizes, finishes and release profiles.
Microparticles are suitable for a broad range of drug delivery applications, and they offer many advantages.
Beads, pellets, granules or mini-tablets offer enormous flexibility in their drug release profiles.
Enhance systemic delivery by directing the release of the API to specific areas of the small intestine or colon.
Looking For Help & Advice?
Talk directly to the Quay staff - Our dedicated team leaders are ready to listen and help with your project.
Our Solubility & Bioavailability Enhancements
Highly experienced in identifying the most suitable lipid excipients for the challenges of dispersion, dissolution or digestion
Particle Size Reduction
Where drugs exhibit reduced bioavailability due to poor solubility, the cause is often intrinsically linked with particle size.
Increase the dissolution, absorption and therapeutic efficacy of drug dosage form that has poor solubility.
Adjustment of the pH value is the simplest and most commonly used method of increasing water solubility of compounds.
Other Solubilisation Technologies
While lipophilic systems, solid dispersions, particle size reduction and pH control are the principal techniques used to overcome solubility difficulties, we have a wide range of other approaches, such as the ones below, which we use where they will offer results that more closely meet the needs of our clients.
Co-solvents are based on the principles of cohesive energy density. Where a drug shows poor solubility in water, its solubility can often be increased by the addition of a water-miscible solvent in which the drug has good solubility.
Complexation uses agents such as cyclodextrins and their derivatives to form intermolecular complexes. These increase the water solubility, dissolution rate and bioavailability of lipophilic drugs for oral or parenteral delivery.
Micellar solubilisation uses solubilising agents capable of forming micellar structures. When the concentration of surfactants exceeds the Critical Micelle Concentration (CMC), the micelles that are then formed trap the drug within their structures in a process known as micellisation.
The addition of an electrolyte that does not possess the same ions can raise the solubility of an electrolyte that has limited solubility.
Your Dedicated Technology Contacts
Dr Alison Foster
Head of Technical - Preclinical
Alison is the Head of Technical for Preclinical Services at Quay Pharmaceuticals. She has a wide breadth of experience having worked previously for Unilever in their cross-category research unit focused on Oral Care and Hair projects, to being one of the founders of a small nanotechnology start-up company focussed on improving bioavailable of poorly soluble drugs. Alison gained Post-Doctoral experience in medicinal chemistry from the School of Pharmacy, the University of Manchester following a PhD in synthetic chemistry. Alison is also co-author of twenty-five patents and nine papers.
Head of Business Development - Preclinical
Audrey has 15 years’ experience within the preclinical contract research world holding both Operational and Commercial positions during that time. Spending six years at CXR Biosciences, Audrey was a laboratory team leader, before joining the sales team as BDM, then Sales Manager. She then joined BD Biosciences as their European Key Account Manager is responsible for both contract services and drug metabolism research products. Before joining Quay Pharma in 2018, Audrey returned to CXR (then Concept Life Sciences) for four years as Principal Scientist and Head of Operations. Audrey has a PhD in Neurosciences.
Your Project Matters To Us
Contact us today and tell us about your challenges - Your project matters to us and we're ready to help.